Navigation Links
Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Date:1/4/2011

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

http://www.reportlinker.com/p0357279/Emerging-Opportunities-in-Biosimilar-and-Biobetter-Drugs-Markets.html

Executive SummaryThe biosimilar and biobetter drugs market has started to position itself in a grand manner following a series of changes in regulatory framework in many countries. The biosimilar market segment represents a host of opportunities to the generics manufacturers to enter in a market, which is largely driven by commands premium prices and unmet needs. Backed by this feature, the market is continuing to outperform the global pharmaceutical market. "Emerging Opportunities in Biosimilar and Biobetter Drugs Markets" provides a detailed overview and a succinct, but deep-dive analysis on the biosimilar and biobetter drugs segments. The report discusses various exclusive features of biobetter drugs and studies their importance in meeting the future demand. It also highlights various emerging trends in the market and relates these with the future market growth.

The key objective of this report is to identify and probe into the emerging opportunities in the biobetter and biosimilar drugs market. It also tries to estimate the opportunities in various biological drugs segments including monoclonal antibodies, Erythropoietin and insulin, thus giving a complete idea about the market dynamics to the target audience of this report.

The report Emerging Opportunities in Biosimilar and Biobetter Drugs Markets also includes information on the key players in the industry and their product portfolio. This will enable the target audience of this report in understanding the contemporary industry scenario. Besides, the report gives complete information on various products whose patents are on the verge of expiration and thus, it is offering huge opportunities for generics manufacturers. Some of the key findings of report are given below:

  • The clause of "12 Year Exclusivity" for biologics in the US healthcare reform bill is going to have a long term impact on the growth of biosimilar drugs market
  • The increasing application of monoclonal antibodies in the cancer treatment is going to boost the demand of biosimilar and biobetter drugs in this market segment

  • Delivery TimeThree Business days

    To order this report:: Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
    2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
    3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
    4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
    5. Reportlinker Adds Nanomedicine Report
    6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
    7. Reportlinker Adds Nanoporous Materials Report
    8. Reportlinker Adds Membrane Bioreactors Report
    9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
    10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
    11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
    (Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
    (Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
    (Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
    Breaking Biology Technology:
    (Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
    (Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
    (Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
    Breaking Biology News(10 mins):